Cancer scientists create 'human' leukemia process to map how disease begins, progressesApril 27, 2007Cancer researchers led by Dr. John Dick at Ontario Cancer Institute (OCI) have developed a method to convert normal human blood cells into "human" leukemia stem cells. The converted cells, when transplanted into special mice that permit the growth of human cells, can replicate the entire disease process from the very moment it begins. The findings are published in the journal Science. Dr. Dick, Senior Scientist at OCI, the research arm of Princess Margaret Hospital, and a Professor in the Department of Molecular Genetics, University of Toronto, said: "Most human leukemia research involves studying a patient's diseased cells or a cell line grown from those cells. However, since cancer takes many months or years to develop, just studying the cells at the end of the process does not let you know what the series of changes were that caused the cells to become leukemic, and when they happened. "With the method we developed, we have duplicated the natural process every step of the way. The method we developed opens the pathway generally to understanding the process of how cancer begins."
The scientific team of Frederic Barabe, James Kennedy and Kristin Hope introduced a specific leukemia gene into normal human stem cells and injected the genetically altered cells into mice that lacked immune systems. The result? 100% of the mice developed fatal leukemia that displayed the same characteristics and patterns of human disease. For the past 20 years, said Dr. Dick, leukemia research has focused mainly on human cells where the disease already exists or by studying leukemia created in mouse cells. This study flipped it around to focus on asking which are the normal cells within which the disease arises and then how it evolves and progresses, all within the context of human cells. "So what we are building is a new approach and way of studying how leukemia arises in the first place. We found that with the leukemia gene we were using, the disease only arose from immature stem and progenitor cells. The leukemic stem cells that were created seemed to change as the human leukemia was grown for longer times in a series of transplanted mice. Our findings of how these leukemic stem cells functioned could explain several features of the leukemia in children and adults that also contain the same leukemia gene, MLL-ENL." In 1994, Dr. Dick identified the first cancer stem cell in leukemia, following on the original discovery in 1962 of the blood stem cell by two other renowned OCI scientists, Drs. Ernest McCulloch and James Till -- a discovery that formed the basis of all current stem cell research. Dr. Dick, who holds the Canada Research Chair in Stem Cell Biology and is also Senior Scientist at the Toronto General Research Institute and at the McEwen Centre for Regenerative Medicine, University Health Network, recently published other findings showing that colon cancer arises from stem cells specific to the tumour. Princess Margaret Hospital | |||||||||||||||||||||
|
Related Leukemia News Articles VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma. New insights into the regulation of PTEN tumor suppression function The PTEN tumor suppressor gene controls numerous biological processes including cell proliferation, cell growth and death. But PTEN is frequently lost or mutated; in fact, alteration of the gene is so common among various types of human cancer that PTEN has become one of the most frequently mutated of all tumor suppressors. Children's national co-leads nationwide study of landmark sickle cell treatment Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease. Newly discovered molecular switch helps decide cell type in early embryo development Researchers have discovered a central molecular switch in fruit fly embryos that opens new avenues for studying the causes of birth defects and cancer in humans. Writing about their study in the Aug. 12 Developmental Cell, scientists at Cincinnati Children's Hospital Medical Center determined the switch to be a main tuning mechanism for instructing cells whether to form sensory nerves or blood cells in different parts of the body. McGill researchers overcome chemotherapy resistance in the lab Researchers from McGill University's Faculty of Medicine have discovered a compound that reduces resistance to chemotherapy agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI). Crucial Factors in Lymphoma Development and Survival Discovered Researchers at National Jewish Medical and Research Center have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer. Leukemia drug could save lives of stroke patients The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms. Stroke study reveals key target for improving treatment and suggests that Gleevec may help For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke. Math could help cure leukemia When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer. Combining math and medicine to treat leukemia Researchers have produced a mathematical model that may lead to the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML). More Leukemia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||